Clinical trial NCT03203837 - References

Hepatocellular Carcinoma — Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere®

Citation(s)

•   Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, Honjo T
  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol. 1996 May;8(5):765-72.
•   Altimari A, Fiorentino M, Gabusi E, Gruppioni E, Corti B, D'Errico A, Grigioni WF
  Investigation of ErbB1 and ErbB2 expression for therapeutic targeting in primary liver tumours. Dig Liver Dis. 2003 May;35(5):332-8.
•   Bassullu N, Turkmen I, Dayangac M, Yagiz Korkmaz P, Yasar R, Akyildiz M, Yaprak O, Tokat Y, Yuzer Y, Bulbul Dogusoy G
  The Predictive and Prognostic Significance of c-erb-B2, EGFR, PTEN, mTOR, PI3K, p27, and ERCC1 Expression in Hepatocellular Carcinoma. Hepat Mon. 2012 Oct;12(10 HCC):e7492. doi: 10.5812/hepatmon.7492. Epub 2012 Oct 11.
•   Boni C, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C
  Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol. 2007 Apr;81(8):4215-25. Epub 2007 Feb 7.
•   Bruix J, Gores GJ, Mazzaferro V
  Hepatocellular carcinoma: clinical frontiers and perspectives. Gut. 2014 May;63(5):844-55. doi: 10.1136/gutjnl-2013-306627. Epub 2014 Feb 14. Review.
•   Castell JV, Gómez-Lechón MJ, David M, Fabra R, Trullenque R, Heinrich PC
  Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology. 1990 Nov;12(5):1179-86.
•   Finkenzeller G, Marmé D, Weich HA, Hug H
  Platelet-derived growth factor-induced transcription of the vascular endothelial growth factor gene is mediated by protein kinase C. Cancer Res. 1992 Sep 1;52(17):4821-3.
•   Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M, Matsuura N
  Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer. 2001 May 18;84(10):1377-83.
•   Jang JW, Oh BS, Kwon JH, You CR, Chung KW, Kay CS, Jung HS
  Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012 Dec;60(3):686-93. doi: 10.1016/j.cyto.2012.07.017. Epub 2012 Aug 18.
•   Lee TY, Kim KT, Han SY
  Expression of ErbB receptor proteins and TGF-alpha during diethylnitrosamine-induced hepatocarcinogenesis in the rat liver. Korean J Hepatol. 2007 Mar;13(1):70-80.
•   Lewis CE, Pollard JW
  Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006 Jan 15;66(2):605-12. Review.
•   Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP
  Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer. 2007 Apr;43(6):979-92. Epub 2007 Feb 8. Review.
•   Ng IO, Lai EC, Fan ST, Ng MM, So MK
  Prognostic significance of pathologic features of hepatocellular carcinoma. A multivariate analysis of 278 patients. Cancer. 1995 Dec 15;76(12):2443-8.
•   Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, Saito T, Togashi H, Kawata S
  Possible contribution of circulating transforming growth factor-beta1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int. 2004 Feb;24(1):21-8.
•   Poon RT, Ng IO, Lau C, Zhu LX, Yu WC, Lo CM, Fan ST, Wong J
  Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg. 2001 Feb;233(2):227-35.
•   Salvi A, Arici B, Portolani N, Giulini SM, De Petro G, Barlati S
  In vitro c-met inhibition by antisense RNA and plasmid-based RNAi down-modulates migration and invasion of hepatocellular carcinoma cells. Int J Oncol. 2007 Aug;31(2):451-60.
•   Stavri GT, Hong Y, Zachary IC, Breier G, Baskerville PA, Ylä-Herttuala S, Risau W, Martin JF, Erusalimsky JD
  Hypoxia and platelet-derived growth factor-BB synergistically upregulate the expression of vascular endothelial growth factor in vascular smooth muscle cells. FEBS Lett. 1995 Jan 30;358(3):311-5.
•   Tada M, Kanai F, Tanaka Y, Tateishi K, Ohta M, Asaoka Y, Seto M, Muroyama R, Fukai K, Imazeki F, Kawabe T, Yokosuka O, Omata M
  Down-regulation of hedgehog-interacting protein through genetic and epigenetic alterations in human hepatocellular carcinoma. Clin Cancer Res. 2008 Jun 15;14(12):3768-76. doi: 10.1158/1078-0432.CCR-07-1181.
•   Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G
  Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6.
•   Talaat RM, Esmail AA, Elwakil R, Gurgis AA, Nasr MI
  Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer. 2012 Jan;31(1):29-35. doi: 10.5732/cjc.011.10258. Epub 2011 Dec 23.
•   Tanabe KK, Lemoine A, Finkelstein DM, Kawasaki H, Fujii T, Chung RT, Lauwers GY, Kulu Y, Muzikansky A, Kuruppu D, Lanuti M, Goodwin JM, Azoulay D, Fuchs BC
  Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA. 2008 Jan 2;299(1):53-60. doi: 10.1001/jama.2007.65.
•   Tang Z, Qin L, Wang X, Zhou G, Liao Y, Weng Y, Jiang X, Lin Z, Liu K, Ye S
  Alterations of oncogenes, tumor suppressor genes and growth factors in hepatocellular carcinoma: with relation to tumor size and invasiveness. Chin Med J (Engl). 1998 Apr;111(4):313-8.
•   Thiery JP, Sleeman JP
  Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42. Review.
•   Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, Ferrari C
  PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol. 2006 Nov;80(22):11398-403. Epub 2006 Sep 6.
•   Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, Cavallo MC, Orlandini A, Missale G, Ferrari C
  Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment. J Hepatol. 2008 Apr;48(4):548-58. doi: 10.1016/j.jhep.2007.12.014. Epub 2008 Jan 28. Erratum in: J Hepatol. 2008 Sep;49(3):483.
•   Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, Tang D, Marubashi S, Miyamoto A, Takeda Y, Umeshita K, Nakamori S, Sakon M, Dono K, Wakasa K, Monden M
  Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int. 2006 May;26(4):414-23.
•   Wenjin Z, Chuanhui P, Yunle W, Lateef SA, Shusen Z
  Longitudinal fluctuations in PD1 and PD-L1 expression in association with changes in anti-viral immune response in chronic hepatitis B. BMC Gastroenterol. 2012 Aug 16;12:109. doi: 10.1186/1471-230X-12-109.
•   Zeng Z, Shi F, Zhou L, Zhang MN, Chen Y, Chang XJ, Lu YY, Bai WL, Qu JH, Wang CP, Wang H, Lou M, Wang FS, Lv JY, Yang YP
  Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS One. 2011;6(9):e23621. doi: 10.1371/journal.pone.0023621. Epub 2011 Sep 1.
•   Zulehner G, Mikula M, Schneller D, van Zijl F, Huber H, Sieghart W, Grasl-Kraupp B, Waldhör T, Peck-Radosavljevic M, Beug H, Mikulits W
  Nuclear beta-catenin induces an early liver progenitor phenotype in hepatocellular carcinoma and promotes tumor recurrence. Am J Pathol. 2010 Jan;176(1):472-81. doi: 10.2353/ajpath.2010.090300. Epub 2009 Dec 11.

Biomarker Analyses in Hepatocellular Carcinoma Patients Treated With Therasphere®

Details for clinical trial NCT03203837